Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Airborne Seasonal

This article was originally published in The Tan Sheet

Executive Summary

Airborne announces the nationwide launch of its new Airborne Seasonal effervescent tablet of vitamins and nutrients intended to promote normal histamine levels, the firm states June 12. The product contains a "natural herbal blend" of quercitin, Chinese skullcap, apple, eleuthero, perilla and peppermint, in addition to vitamins C and B6, according to Airborne. An advertising and marketing campaign to support the new product may follow the launch, but plans are still in the developmental stage, the company says. A box of 16 tablets carries an SRP of $9.99...

You may also be interested in...



Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel